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UK. The death rate from carcinoma of the lung in the UK
increased progressively, with a 15 - 20-year lag period behind
the rising tobacco consumption. Many studies, including nine
prospective surveys, have shown that the possibility of death
from lung cancer increases as the number of cigarenes smoked
increases. The consistency of the epidemiological evidence,
together with the dose-response relationship and the fact that
numerous carcinogens are known to be present in cigarene
smoke, provide the basis for the now unequivocally accepted
relationship between smoking and lung cancer.8 There is also
evidence to suggest that the risk of developing lung cancer
increases with earlier age of ons.et of smoking and with the
dose of carcinogens present in cigarettes. The early onset of
smoking in South African schoolchildren and the high tar and
nicotine content of South African cigarettes are thus cause for
great concern.9 The combination of cigarene smoking and
failure to prevent death from pulmonary infections, in particular
tuberculosis, higWights the deficiencies in the preventive and
curative health services in the RSA. Major changes need to be
made to our health care system to rectify these deficiencies. 7
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Epidemiological research methods
Part VI. Planning a research project
J. L. BOTHA, D. YACH
'There is something extraordinarily satisfying in design-
ing an RCT of "place of therapy", writing the protocol
in such a way as to avoid all the ethical pitfalls, persuad-
ing all the necessary people to participate, and checking
to see that no one cheats.'
Thus wrote Cochrane in 1971. 1 The need for writing a good
protocol is still paramount and applies not only to randomised
controlled trials (RCTs), but to all research projects. Writing a
good protocol reflects good planning, and in this paper we
address some vital aspects of planning a study and writing a
protocol. The information given here should be augmented by
referring to earlier articles in this series,2-6 as well as guidelines
published elsewhere.7- 15
'Protocol', as used here, refers to a written record of the
rationale for the study, and 'of the activities and procedures
planned for use in the study, including a standardised form for
recording the observations. In writing a protocol, the researcher
has to state his/her ideas explicitly, and has to anticipate and
pre-empt problems that may occur in the execution of the
study, and/or' in the analysis and interpretation of the results.
Writing the protocol provides an opportunity for the researcher
to sharpen or re-examine his/her own concepts. The wrinen
Institute for Biostatistics of the South African Medical
Research Council and Departments of Community Health,
University of Stellenbosch, Parowvallei, CP, and University
of Cape Town
J. L. BOTHA, M.B. CH.B., M.Se. (CLIN. EPlD.)
D. YACH, M.B. CH. B., B.se. HONS (EPlD.), M.P.H.
protocol also serves as a means to obtain constructive criticism
from peers at a stage when suggested changes can still be
accommodated. During the execution of me study the protocol
serves as a reference document of decisions made and how and
why mey were made. This helps to avoid inconsistency in ad
hoc decision-making, particularly with changes in research
staff.
We write here of 'a protocol' as if it is a single document
produced once only, and for all time. We do not mean to
create such an impression: a protocol is a dynamic document,
developing with planning, peer review and pilot studies, and
improving all the time under the rigours of the research memods
to be used. On the other hand, a draft of the protocol may
have to be used for a specific purpose at a given time as if it is
a fmal document, e.g. to meet a deadline for fund applications.
We suggest that when writing or reading a protocol, me
writer or reader should be in a position to answer the six
questions discussed in detail below.
1. Is the research question relevant?
This question implies knowledge of the content area of the
proposed research. Such knowledge should be demonstrated
in the protocol by explaining why the research idea is a good
one. A literature review should form part of mis motivation, to
demonstrate that the researcher is aware of previous and
current attempts to answer the same question. In surveying
published work, both the content and the research methods
should be reviewed. The implications and practical relevance
of study results should be clearly spelt our in the protocol.
When using a protocol to apply for funds, researchers
should be aware of the criteria used to decide on funding,
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especially if many funding agencies exist. Cancer researchers
should know that a funding agency for cancer research exists,S
and diabetes researchers should know about funding for
diabetes research. In countries such as the RSA, where the
bulk of research funding comes from a few agencies, which
may have as their source public (taxpayers') money, care
should be taken to use clear, content-based and methodological
criteria. The other five questions discussed in this paper
incorporate clear methodological criteria.
Content-related criteria are difficult to propose where many
researchers from different content areas compete for funding
from the same source. We wish to suggest some common-sense
guidelines often used in deciding on the relevance of epi-
demiological research. We believe they have wider applica-
bility.
What is the impact of the problem?
The greater the number of people affected, the greater the
number of people who can benefit from a solution. Examples
are: mortality in black children, and cardiovascular disease in
other population groups.
Is the problem amenable to intervention?
Problems for which interventions of proven benefit exist
deserve priority, particularly in health care research, or in
areas where prevention is possible. Examples are: child morta-
lity, tuberculosis and hypertension.
Will action follow the results?
Problems which health care authorities (official or com-
munity-based) are willing and able (financially and in terms of
manpower) to tackle should have higher priority than those
they are loath or unable to address.
Does the project present a unique opportunity
for research?
If the research cannot be done elsewhere, either because the
problem is unique to the RSA, or because the technique is
orily avaIlable locally, the project should be given higher
priority.
2.· Is the project feasible?
The feasibility of a project can be seen to have three compo-
nents: epidemiological, logistical and ethical.
Epidemiological feasibility is present if three questions
can be answered in the affirmative:
Can an answer TO The research question be obTained by using the
chosen STUdy d~sign? The chosen ctesign should be clearly stated
with the reasons for that choice, remembering that descriptive,
analytical and intervention studies are done to obtain answers
to different types of questions. 2- 4 Similarly, the reasons for
choosing a particular type of analytical studi,6 should be
stated.
Is the proposed sample size large enough so that the chance of
missing a clinically meaningful difference will be small? The
chance referred to here is also known as the type II error and
is often denoted by beta. Its complement (I-beta) is often
referred to as the power of the test in not missing real
differences, and should be specified in the protocol. A probabi-
lity of 0,1 or 10% of missing a real difference is acceptable to
most researchers.
Is The proposed sample size so large ThaT The chance of picking
up a clinically meaningless difference as sTaTisTically significanr
will be large? The chance referred to here is also known as the
type I error and is often denoted by alpha. It is seen in the
analysis as the P value, and should be specified in the protocol.
A probability of 0,05 or 5% of this occurring is acceptable to
most researchers.
In practice, these last two questions about sample size can
only be answered if the sample size estimation procedure is
clearly shown in the protocol.
Logistical feasibility is present if the proposed work can
reasonably be expected to be completed by the existing man-
power resources (or those budgeted for) in the time allocated.
In the protocol the budget should be clearly spelt out, detailing
salaries of staff, costs of travelling (including the cost of
anending conferences), and amounts ·set aside for equipment,
computing, publication, stationery, and other running expenses
(e.g. stamps and phone calls). The scheduling of activities
(who does what, when and where), and the duties of each team
member should be indicated.
Ethical feasibility is present if the proposed project con-
forms to the ethical principles generally agreed on, either
intemationallyl6 or 10cally.17 In community-based studies it is
particularly important to obtain community consent and
participation, in the RSA often from formal as well as informal
community leaders. When the proposed project is a randomised
trial of one kind or another, ethical considerations relating to
allocation of patients with informed consent have high
. • 18-20prIOrIty.
3. Will the results be valid?
The validity (or accuracy) of a study's results is defined as
their closeness to the true or real situation. Lack of validity is
described as a bias, or systematic deviation from the truth.
Such a bias can arise from many sources,21 and the steps
which will be taken to avoid applicable biases should be clearly
spelt out in the protocol. We will concentrate on biases from
two major sources: sampling and measurement.
Sampling bias
Sampling bias, or systematic sampling error, occurs if the
selected sample is unrepresentative of the population of interest,
which means that sampled individuals differ systematically
from those not sampled. For valid inferences to be made about
a population effect from an estimate of that effect in a sample,
the sample must be representative of that population. The
likelihood of obtaining a representative sample is high if some
form of randoin sampling is used. 3 It is therefore important
that the researcher specifies clearly in the protocol what target
population he/she has in mind, whether a sample will be used
and how such a sample will be drawn. In addition, the
researcher should indicate how the representativeness of the
sample can be validated, e.g. against census information. This
is necessary for all types of study design in which samples are
drawn.
If the study design is analytical, i.e. two or more groups are
being compared with regard to a previously specified hypo-
thesis, sampling bias can arise from lack of comparability of
the groups~21 For the researcher to be able to ascribe an
observed difference in outcome between two groups to a
particular putative determinant of that outcome, the two groups
should differ with respect to that putative determinant alone.
They should be comparable with respect to all other variables
(or research procedures) which may be associated with that
determinant and which may also determine the outcome.
Steps taken to ensure or check the comparability of the study
groups should also be clearly specified in the protocol. These
steps differ according to the study design used: if it is an
intervention study,4 some form of random allocation is desir-
able; if a case-controlS or follow-up study,6 other options (e.g.
matching or prognostic stratification) should be considered.
Measurement bias
Measurement bias, or systematic measurement error, occurs
when, for example, an observer or instrument measures an
attribute in the same individual repeatedly higher, or repeatedly
lower, than the true value. To find out whether measurement
bias occurs, measurements taken as they would be in the study
should be compared against measurements taken on the same
subjects under the same conditions but using the 'gold standard'
of measurement. Examples of such criterion-related validity
are: 'How closely does the patient's recall of health care
utilisation agree with documented utilisation for the same time
period?', or 'How closely does the indirect measurement of
blood pressure (with cuff and stethoscope) agree with the
simultaneous intra-arterial blood pressure?' This implies that
the true value must be measurable to assess validity; it certainly
is the only way to find out how close to the truth the
measurements really are. In a protocol, validation procedures,
preferably involving a 'gold standard', should be clearly speci-
fied.
Sometimes no 'gold standard' exists, or the attribute to be
measured is abstract, as is often the case with questionnaire
items. Criterion-related validity cannot be estimated in such
cases, and a second-best validation procedure called construct
validity must be used. Here a manifestation of the attribute is
substiroted for the truth in _an hypothesis constructed about
the relationship between the attribute and its manifestation.
For example, we may wish to measure the arrribute 'satisfaction
with health care', for which the truth is not measurable. A
manifestation of this attribute may be use of the same service
on a furore occasion, and we could include a question on the
respondent's intent to do just that. The measurement of
satisfaction can then be validated against a manifestation of
satisfaction, by examining the hypothesis that satisfaction with
health care is associated with the intent to use the same service
in furore.
Sometimes neither criterion-related nor construct validity is
feasible, and then even weaker validation procedures need to
be used. Content validity refers to the apparent comprehensive-
ness of a measure, e.g. does a measure of the use of physician's
services tap referrals, hospitalisations and casualty visits as
well as primary care visits? Face validity is even weaker and
refers to the credibility of the measure: does a measure of
social function include questions about interactions with other
people? These validation procedures should b", specified in a
protocol only if neither criterion-related nor construct validation
is feasible.
Other important design-specific sources of bias, e.g. non-
response, are discussed in detail elsewhere.4- 6.21
4. Will the results be reliable?
Reliability (precision, reproducibility or repeatability) is defined
as the closeness of repeated measurements of the same attribute
to one another. The true siroation has no bearing on the
reliability of results. Lack of reliability is termed random error
or variation and can arise from at least two major sources,
sampling and measurement. The steps taken to minimise
random error due to these factors should be clearly spelt out in
the protocol.
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Random sampling error
This reflects the variation around the true situation that
would occur if many different random samples were taken
from the target population and the results estimated from
each. Generally speaking, precision can be improved by
increasing the sample size, keeping in mind the earlier
comments on epidemiological feasibility. In the protocol, the
reasoning behind the suggested sample size should be made
clear. .Sample si~e can be estimated duri~g plann,i,n,& by a
statlstlClan or epidemIOlogist, or looked up III tables··'·' if the
researcher provides four pieces of information: (I) the size of
the expected effect or that which would be meaningful; (i/) the
size of the random error or variation to be expected; (iil) the
chance he/she is prepared to take in falsely saying there is an
effect (alpha); and (iv) the chance he/she is prepared to take in
missing a real effect (beta).
The general idea in using this information to estimate an
optimum sample size can be seen from the following formula:
n = k (noise/signal),
where n is the sample size; k is a coefficient incorporating
alpha and beta, as well as the characteristics of the statistical
test to be used; noise is an estimate of the random variation
(e.g. standard deviation); and signal is the expected (meaning-
ful) difference between groups.
From this it is clear that the larger the random variation, the
larger the sample size required for statistical significance for a
given difference will be, and vice versa. Similarly, the larger
the sample size required for statistical significance for a given
variation, the smaller the difference will be, and vice versa.
Not so clear from this formula is the fact that the sample size
required will be larger the smaller either the alpha or the beta
value (or both) specified by the researcher. In practice, a
single sample size is not estimated, but rather a range of
sample sizes, using realistic variation in the abovementioned
four pieces of information. The research can then decide how
large a sample to use, given his/her resources and given the
limitations imposed by the stipulated values for alpha, beta,
the signal and the noise. The first two pieces of information
often have to be estimated in a pilot study.
Random measurement error
This refers to the concordance reached in repeated measure-
ments (in this pure sense, irrespective of how close to the true
value they are). There are usually three parties involved in a
measurement, giving rise to four possible sources of error.
Inter-observer reliability refers to the concordance between
two (or more) observers if they use the same instrument under
the same' conditions to meisure an attribute in the same
individual. Intra-observer variation refers to the concordance
between two (or more) measurements of the same attribute in
the same individual by the same observer using the same
instrument under the same conditions. The same types of
variation can occur with regard to the instrument, the subject,
or the interpretation of the readings or responses. In the
protocol, steps planned or taken to quantify [his variation in a
pilot study and/or in the final study should be specified. In
addition the way in which this information will be or has been
used should be specified, e.g. to standardise instruments, train
and/or select interviewers, or adjust results. Examples of such
sources of variation and techniques to quantify them are
described elsewhere.24- 27
5. Will appropriate analysis and
interpretation be possible?
The answer to this question is inextricably bound with some
of the issues mentioned under the first four questions, notably,
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epidemiological feasibility (particularly sample size estimation),
validity and reliability of results. However, there are some
additional issues to consider here even if the earlier questions
can be answered satisfactorily.
Details of data capture and management must be given. If
data are to be analysed by computer, a pro forma should be
enclosed with the protocol, and the computer and analysis
package named, as well as the people who will do the analysis
(if not the researcher). It is particularly important for the
researcher to draw up some dummy tables of expected results.
This may alert the researcher to tables that carmot be drawn
up because the necessary data have not been collected, or
because the necessary data have been collected, bur in the
wrong format. Urmecessary data may be identifted in this way,
and dropped, thereby increasing the feasibility of the study. In
addition, specific objectives are often clarified by the act of
drawing up such tables. In this respect it is useful to specify
clearly in terms of the stated hypothesis which are to be
regarded as response (dependent) variables, which as explana-
tory (independent) variables and which as interfering (con-
founding) variables. This tends to make researchers aware of
how many different tables (combinations of variables) are
possible, and may force them to consider only important issues
for investigation or to consider obtaining statistical advice in
the plarming stage (perhaps even abour multivariate analysis).
6. Are pilot studies being planned or have
some been done?
This is an important issue and is mentioned separately to
emphasise that enough time should be set aside to allow for
plarming the study, pretesting procedures and modifying the
protocol before the ftnal study. There should be enough time
to do more than one pilot study if necessary.
Earlier, mention was made of pilot studies when considering
the logistical feasibility, the validity and reliability of results,
and the analysis and interpretation of results. All these objec-
tives carmot be met in a single pilot study: (i) to test the
logistical feasibility of the study, the exact protocol proposed
for the ftnal study needs to be executed; (iz) to validate results
against a 'gold standard', subjects known to have a range of
values when measured by this standard need to be measured
by the test measurement as well to see how well they compare
over the full range of possible values; (iil) to obtain information
on the size of random error and of the expected effect for
estimation of the required size, a random sample of the target
population to be used in the final study needs to be drawn and
measured; (iv) to quantify inter-observer error the same indi-
viduals need to be observed by different observers - these
individuals need not be representative of the target population;
and (v) to assess the feasibility of data capture, management
and analysis, data from a pilot study should be pur through
the proposed analysis.
These pilot studies clearly carmot all be done on the same
group of patients, and only after the other pilot studies have
been executed and the final protocol decided on can the
feasibility studies be done.
How many subjects should be used in a pilot study?
Clearly, fewer subjects should be used than in the ftnal study,
otherwise the budget for pilot studies would exceed that for
the ftnal study. It is best to consult with an epidemiologist or
statistician in every case since requirements may vary depending
on the availability of subjects, type of ourcome and the aim of
the pilot study.
Can the data from a pilot study be added to those of
the final study? This can be done only if the subjects or
methods used in the pilot study do not differ from those in the
ftnal study. In practice these conditions are rarely, if ever, met
because pilot studies are run expressly to fmd out ho~' to
change methods for the bener.
Concluding remarks
When writing a protocol it is useful to try to ascertain how
readers will evaluate the protocol. The protocol should there-
fore be reviewed and during such review all six questions, with
sub-questions, should receive answers in the afftrmative before
the protocol can be labelled ideal or perfect. In practice if the
protocol is read with funding in mind, the ftrst four questions
at least, have a hierarchy built into them: (I) if question I is
not relevant, the project should not be funded; (il) if question
2 is relevant, but not feasible, the project should not be
funded; (iil) if question 3 is relevant and feasible, bur results
are invalid, it should not be funded until validity has been
improved; and (iv) if question 4 is relevant, feasible and valid,
bur the results are unreliable, there should be no funding until
reliability has been improved.
REFERENCES
I. Cochrane AL. Effectiveness and efficiency. In: Random RefleClions on Healrh
Services. London: The . Juffield Provincial Hospitals Trusr, 1971.
2. Botha JL, Yach D. Epidemiological research methods: Parr I. Why epi-
demiology? S Afr MedJ 1986; 70: 267-270.
3. Botha JL, Yach D. Epidemiological research methods: Parr 11. Descriptive
studies. S Afr Med] 1986; 70: 766-767.
4. Botha JL, Yach D. Epidemiological research methods: Parr Ill. Randomised
controlled trials (for interventions). S Afr MedJ 1987; 71: 657-660.
5. Yach D, Botha JL. Epidemiological research methods: Parr IV. Case-eonrrol
studies. S Afr MedJ 1987; 71: 763-766.
6. Yach D, Botha JL. Epidemiological research methods: Parr V. Follow-up
studies. S Afr MedJ 1987; 72: 266-269.
7. Spitzer WO. Ten tips on preparing research protocols. Can Nurse 1973; 69:
1-4.
8. Yach D, Hessel PA. The research protocol in epidemiologicliJ studies:
lessons from the review of 10 examples. S AfrJ Epidemiol 1987 (in press).
9. Stolley PD, Schlesselman 11. Planning and conducting a study. In: Schlessel-
man 11, ed. Case-Comrol SlUdies: Design, Conducc, Analysis. New York:
Oxford Universiry Press, 1982: 69-104.
10. Burr ML. Criteria for planning a research project. Communicy Med 1979; 1:
157-159.
I!. Liechtenstein M], Mulrow CD, Elwood Pc. Guidelines for reading case
control studies.J Chron Dis 1987; 40: 893-903.
12. Gore SM. Statistics in question: assessing clinical trials - protocol and
monitoring. Br MedJ 1981; 282: 369-371.
13. Zelen M. Guidelines for publishing papers on cancer clinical trials: responsi-
bilities of editors and authors.J Clin Onco11983; 1: 164-169.
14. Botha JL. How nor to do clinical trials. S AfrJ Hosp Med 1982; 8: 122-126.
15. Gardner M], Machin D, Campbell MJ. Statistics in medicine: use of check
lists in assessing the statistical content of medical studies. Br Med J 1986;
292: 810-812.
16. Bankowski Z, Howard-Jones _J. Human Experimentation and Medical Ethics.
Geneva: Council for International Organisations of Medical Sciences, 1982.
17. Lochner JdeV. A Guide to Echical Considerations in Medical Research.
Parowvallei, CP: South African Medical Research Council, 1979.
18. Zelen M. A new desigo for randomized clinical trials. N Engl J Med 1979;
300: 1242-1245.
19. Smith W, Zelen M, Smith W. Randomization and optimal desigo (Corre-
spondence). J Chron Dis 1983; 36: 609-612.
20. Hessel PA. Ethical issues in epidemiological research. S Afr MedJ 1987 (in
press).
21. Sackett DLS. Bias in analytic studies.J Chron Dis 1979; 32: SI-53.
22. Fleiss JL. Stacistical Methods for Races and Proporcions. New York: John
Wiley, 1981: 260-280.
23. Sackett DLS, Haynes RB, Tugwell P. Clinical Epidemiology: A Basic Science
for Clinical Medicine. Boston: Little, Brown, 1985: 186-/87.
24. Deparrment of Clinical Epidemiology and Biostatistics, McMaster Universiry.
Clinical disagreement: I. How often it occurs and why. Can Med Assoc J
1980; 123: 499-504.
25. Department of Clinical Epidemiology and Biostatistics, McMaster Universiry.
Clinical disagreement. 11. How ro avoid it and how ro le~rn from one's
mistakes. Can Med AssocJ 1980; 123: 613-617.
26. Koran LM. The reliabiliry of clinical methods, data and judgements: parr I.
N EnglJ Med 1975; 293: 642-646.
27. Koran LM. The reliabiliry of clinical methods, data and judgements: parr
I I. N EnglJ Med 1975; 293: 695-70 I.
